Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-6: Durvalumab After Sequential Chemoradiation in Unresectable Stage III NSCLC
2018-002220-16Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Grade 3 or Grade 4 treatment-related adverse events within 6 months. Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-002220-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002220-16.